保健医学研究与实践2025，Vol.22Issue(3)：34-40,7.DOI:10.11986/j.issn.1673-873X.2025.03.06
表柔比星联合环磷酰胺序贯多西他赛新辅助化疗治疗乳腺癌的疗效观察
Efficacy observation of epirubicin combined with cyclophosphamide sequential docetaxel neoadjuvant chemotherapy for breast cancer
摘要
Abstract
Objective To investigate the efficacy of epirubicin combined with cyclophosphamide sequential docetaxel neoadju-vant chemotherapy for breast cancer,aiming to provide references for clinical treatment.Methods A total of 126 female breast cancer patients admitted to Xi'an International Medical Center Hospital from November 2019 to July 2021 were select-ed as study participants.According to chemotherapy regimens,patients were allocated to a control group(n=62;epirubicin combined with cyclophosphamide and docetaxel)and a study group(n=64;epirubicin combined with cyclophosphamide se-quential docetaxel).After treatment completion,therapeutic efficacy was compared between groups;carbohydrate antigen 153(CA153),tumor-specific growth factor(TSGF)levels,and Quality of Life Questionnaire-Breast Cancer 23(QLQ-BR23)scores before and after treatment were compared.Moreover,toxic and adverse reactions during treatment,1-year and 3-year survival rates after discharge,and surgical completion rates were compared.Results The overall response rates were 68.75%in the study group and 59.68%in the control group,showing no statistically significant difference(P>0.05).Compared with pre-treatment,CA153 and TSGF levels significantly decreased in both groups post-treatment(P<0.05),but intergroup differences were not statistically significant(P>0.05).Before treatment,no differences were noted in body image,breast symptoms,arm symptoms,sexual functioning,or systemic therapy reaction scores between groups(P>0.05).At post-treatment,all of these scores improved compared to pre-treatment in both groups(P<0.05),but no intergroup differences were observed in body image,breast symptoms,arm symptoms,or sexual functioning scores(P>0.05).Systemic therapy reaction scores were significantly lower in the study group than in the control group(P<0.05).Post-treatment incidences of neutropenia,thrombocytopenia,and nausea/vomiting were significantly lower in the study group than in the control group(P<0.05).The 1-year survival rate was significantly higher in the study group than in the control group(P<0.05),while no significant difference was found in the 3-year survival rate(P>0.05).No significant difference was observed in surgical completion rates between groups(P>0.05).Conclusion For neoadjuvant chemothera-py in breast cancer patients,the concurrent regimen(epirubicin in combination with cyclophosphamide and docetaxel)and sequential regimen(epirubicin in combination with cyclophosphamide sequential docetaxel)demonstrate comparable effica-cy.However,sequential administration shows reduced toxicities,improves systemic therapy reaction to a certain extent,and is worthy of clinical promotion.关键词
表柔比星/环磷酰胺/多西他赛/乳腺癌/新辅助化疗/疗效Key words
Epirubicin/Cyclophosphamide/Docetaxel/Breast cancer/Neoadjuvant chemotherapy/Efficacy分类
医药卫生引用本文复制引用
刘追星,杨洋,黄振家,胡双双,李丹,陈卓,王心丽,陈光伟..表柔比星联合环磷酰胺序贯多西他赛新辅助化疗治疗乳腺癌的疗效观察[J].保健医学研究与实践,2025,22(3):34-40,7.基金项目
陕西省自然科学基础研究计划项目(2023-JC-QN-0981). （2023-JC-QN-0981）
